Race and Ethnicity Often Not Reported in Clinical Trials for Mental Health Medications
A recent comprehensive review led by the University of Southampton has highlighted a significant gap in the reporting of race and ethnicity data in clinical trials for mental health and neurodevelopmental treatments. The study, published in JAMA Psychiatry, analyzed over 1,600 randomized controlled trials and found that only approximately 39% of them included information on participants’ racial or ethnic backgrounds. This lack of detailed demographic reporting is particularly concerning for underrepresented groups such as Hispanic, Asian, and Black populations, especially within U.S.-based studies.
The absence of consistent data on race and ethnicity limits our understanding of how different populations respond to mental health medications, impeding the development of tailored and effective treatments. Dr. Alessio Bellato emphasized the importance of recognizing variations among racial and ethnic groups to improve efficacy and tolerability of therapies. The study also revealed that although reporting on race and ethnicity has increased in the U.S. since 1980, progress remains uneven globally, with many regions still lacking comprehensive demographic data.
Most of the trials reviewed—over 375,000 participants—were conducted in Europe and the United States. The researchers stress the need for international guidelines to improve the reporting standards and promote equitable recruitment across diverse populations. Such measures would enhance the generalizability of research findings and ensure treatments are effective for all.
Senior author NIHR Research Professor Samuele Cortese called for global efforts to establish better reporting practices in scientific publications and clinical trials. This initiative aims to reduce biases, improve inclusivity, and better serve diverse patient populations worldwide.
For more details, see the study titled "Reporting and Representation of Race and Ethnicity in Clinical Trials of Pharmacotherapy for Mental Disorders" in JAMA Psychiatry (2025). Source: https://medicalxpress.com/news/2025-05-ethnicity-trials-medications-mental-health.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Enhancing Suicide Prevention Training for Pharmacists: Strategies and Insights
This article explores strategies to enhance suicide prevention training for pharmacists by incorporating lived experience insights, fostering empathy, and improving mental health support in pharmacy practice.
Inner Speech Therapy Offers New Hope for Managing Emotions in Autistic Children
A groundbreaking study suggests that teaching autistic children to develop inner speech may significantly improve their emotional regulation and reduce outbursts, offering new hope for managing autism-related emotional challenges.
Study Reveals Significant Decline in Youth Mental Health in England
A groundbreaking report uncovers a rapid decline in mental health among young people in England, driven by social and economic factors, emphasizing the need for systemic change.
Enhancing Mental Health Integration in Primary Healthcare: Insights from a South African Study
A new study from South Africa highlights effective models and challenges of integrating mental health services into primary healthcare to improve access and outcomes for individuals with serious mental illnesses.